Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
细胞生物学 药物研究
/
细胞凋亡
动物造模剂 药物分析 小分子阳性药 DNA损伤 细胞凋亡
/
神经系统模型
细胞凋亡诱导剂 药物标准品 抗肿瘤 DNA烷基化剂/交联剂 炎症模型
/ Cisplatin/顺铂

Cisplatin/顺铂 {[allProObj[0].p_purity_real_show]}

货号：A210558 同义名： 顺-二胺二氯铂(II) / cis-Platinum; CDDP

Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts. It is used, alone or in combination therapy, in the treatment of several types of cancer, including testicular, ovarian, cervical, bladder, and lung cancers. Cisplatin also inhibits the RecA recombinase of M. tuberculosis (IC50 = 2 µM), blocking protein splicing and cell growth.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Cisplatin/顺铂 化学结构 CAS号：15663-27-1
Cisplatin/顺铂 化学结构
CAS号：15663-27-1
Cisplatin/顺铂 3D分子结构
CAS号：15663-27-1
Cisplatin/顺铂 化学结构 CAS号：15663-27-1
Cisplatin/顺铂 3D分子结构 CAS号：15663-27-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Cisplatin/顺铂 纯度/质量文件 产品仅供科研

货号：A210558 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

更多 >

Cisplatin/顺铂 生物活性

靶点

  • DNA synthesis

  • DNA synthesis
描述 Cisplatin (CDDP) is an antineoplastic chemotherapy agent, primarily by forming cross-links with DNA and thus inflicting DNA damage within cancer cells. Cisplatin triggers ferroptosis and induce autophagy, contributing to its effectiveness against various cancer types[1].[2].[3].

Cisplatin/顺铂 动物研究

Animal study In a study involving melanoma-bearing mice, Cisplatin administration (4 mg/kg B.W.) effectively reduced the size and weight of solid tumors. Moreover, supplementing Cisplatin treatment with HemoHIM further decreased both tumor size and weight, highlighting a potential synergistic effect[3].Cisplatin treatment also results in notable adverse effects on kidney function, as demonstrated in a study where its administration significantly increased kidney weight as a percentage of total body weight, urine volume, serum creatinine, and blood urea nitrogen levels by approximately 132, 315, 797, and 556%, respectively, compared to control rats[4].

Cisplatin/顺铂 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02128282 Cholangiocarcinoma Phase 1 Phase 2 Recruiting November 2021 United States, Arizona ... 展开 >> Mayo Clinic Recruiting Scottsdale, Arizona, United States, 85259-5499 Contact: Mayo Clinic Clinical Trials Office    855-776-0015       Principal Investigator: Mitesh Borad, M.D.          United States, Colorado University of Colorado- Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Amy Szilard    720-848-0702    Amy.Szilard@ucdenver.edu    Principal Investigator: Sarah (Lindsey) Davis, MD          United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Mayo Clinic Clinical Trials Office    855-776-0015       Principal Investigator: Kabir Mody, MD          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mayo Clinic Clinical Trials Office    855-776-0015       Principal Investigator: Joleen Hubbard, MD          United States, Texas Texas Oncology - Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States, 75246 Contact: Tammy Carmical, RN    214-370-1937    tammy.carmical@usoncology.com    Principal Investigator: Carlos Becerra, M.D.          Texas Oncology-Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Karen Poe, RN    903-579-9869    karen.poe@usoncology.com    Principal Investigator: Donald A Richards, M.D.          Korea, Republic of Asan Medical Center Recruiting Seoul, Songpa-gu, Korea, Republic of, 138-736 Contact: Heung-Moon Chang, MD    82-3010-3219 ext 3210    changhm@amc.seoul.kr    Contact: Seok kyung Jeong    82-2-3010-5634    jsk0213@amc.seoul.kr    Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Eunyou Lee    82-2-3410-0955    ley0709@samsung.com    Principal Investigator: Joon Oh Park, MD          Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Myoungsun Choi    82-2-2072-7612    iamyou3@hanmail.net    Principal Investigator: Do-Youn Oh, MD          Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of Contact: So Young Hwang    82-2-2228-8180    syhwang@yuhs.ac    Principal Investigator: Sun Young Rha, MD          Taiwan China Medical University Hospital Recruiting Taichung City, Taiwan Contact: Pei-Chen Hsu    +886-4-2205-2121    peggyshiu0807@gmail.com    Principal Investigator: Li-Yuan Bai, M.D. 收起 <<
NCT00915382 Advanced Gastric Cancer Phase 3 Completed - Korea, Republic of ... 展开 >> Department of Oncology, Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 <<
NCT03427359 Nasopharyngeal Carcinoma Phase 2 Completed - -

Cisplatin/顺铂 参考文献

[1]Wang X, et al. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000 Dec 15;275(50):39435-43.

[2]Cummings BS, et al. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther. 2002 Jul;302(1):8-17.

[3]Park HR, et al. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009 Mar 17;9:85.

[4]Shimeda Y, et al. Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull. 2005 Sep;28(9):1635-8.

Cisplatin/顺铂 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.33mL

0.67mL

0.33mL

16.66mL

3.33mL

1.67mL

33.33mL

6.67mL

3.33mL

Cisplatin/顺铂 技术信息

CAS号15663-27-1
分子式Cl2H6N2Pt
分子量 300.05
SMILES Code Cl[Pt]Cl.N.N
MDL No. MFCD00011623
别名 顺-二胺二氯铂(II) ;cis-Platinum; CDDP; CACP; cis-Diamminedichloroplatinum; DDP; cis DDP; cis-diamminedichloroplatinum II; NSC 119875; cis-Diaminodichloroplatinum
运输蓝冰
InChI Key DQLATGHUWYMOKM-UHFFFAOYSA-L
Pubchem ID 2767
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Inert atmosphere,2-8°C
溶解方案 配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案一
动物实验配方

PO 0.5% CMC-Na 85 mg/mL suspension

Tags: Cisplatin | cis-Platinum;CDDP;CACP;cis-Diamminedichloroplatinum;DDP;cis DDP;cis-diamminedichloroplatinum II;NSC 119875;cis-Diaminodichloroplatinum | 顺-二胺二氯铂(II) | Apoptosis Inducer | Inflammation Model | Nervous System Model | Drug Standard | Anti-tumor | DNA Alkylator/Crosslinker | AmBeed-信号通路专用抑制剂 | Cisplatin/顺铂 纯度/质量文件 | Cisplatin/顺铂 生物活性 | Cisplatin/顺铂 动物研究 | Cisplatin/顺铂 临床数据 | Cisplatin/顺铂 参考文献 | Cisplatin/顺铂 实验方案 | Cisplatin/顺铂 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z